Investigational drug · Phase 2
SHR-4849
Not approved by FDA. In 2 industry-sponsored Phase 2 or 3 trials that are active or finished in the last two years, most often for Malignant Solid Tumors.
Phase 2Last checked: Nov 19, 2026Latest source record: Mar 3, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
2
2 still active
All registered trials
3
Any phase or sponsor naming "SHR-4849"
First trial start
2025
Jul 8, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "SHR-4849", any sponsor or status.
Conditions studied
As listed on its trial records.
- Malignant Solid Tumors
Approved drugs for the same conditions: Oncology
Largest trials
Live from ClinicalTrials.gov: studies naming "SHR-4849" as an intervention, largest first.
Shanghai Hengrui Pharmaceutical Co., Ltd.Industry
NCT07268040 · 400 participants (planned) · Start Dec 23, 2025 · Primary completion Dec 2028
Drug: SHR-7787 Injection; SHR-1316 Injection and 5 more · For: Malignant Solid Tumors
Sites: Wuhan, China; Shanghai, China
- A Trial of SHR-4849 Combined With Other Antitumor Drugs in Patients With Malignant Solid TumorsRecruiting
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT07028281 · 120 participants (planned) · Start Jul 8, 2025 · Primary completion Dec 2028
Drug: SHR-4849、SHR-1316、SHR-8068、BP102、carboplatin、cisplatin · For: Malignant Solid Tumors
Sites: Jinan, China
Suzhou Suncadia Biopharmaceuticals Co., Ltd.Industry
NCT06443489 · 80 participants (planned) · Start Jun 26, 2024 · Primary completion Dec 2026
Drug: SHR-4849 · For: Advanced Solid Tumors
Sites: Jilin City, China
Newest research
PubMed records naming it or its code names, newest first.
No PubMed records name it yet, which is common for early code-named drugs.
Also in development for Malignant Solid Tumors
- AdebrelimabSHR-8068, HRS -4642Phase 341 trials
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Non-small Cell Lung Cancer, Advanced or Metastatic Non-small Cell Lung Cancer, Advanced Solid Tumors
- SHR-7787Phase 23 trials
Shanghai Hengrui Pharmaceutical Co., Ltd. · Malignant Solid Tumors, Limited-stage Small-cell Lung Cancer, Advanced Solid Tumors
- SHR-1681Phase 21 trial
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors
- SHR-4298Phase 21 trial
Suzhou Suncadia Biopharmaceuticals Co., Ltd. · Malignant Solid Tumors
- TAK-505Phase 21 trial
Takeda · Malignant Solid Tumors
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.